Radiosensitizing potential of the selective cyclooygenase-2 (COX-2) inhibitor meloxicam on human glioma cells

Journal of Neuro-Oncology

Volumn 85, Issue 1, 2007, Pages 25-31

  Bijnsdorp, Irene V ^a   van den Berg, Jaap ^a   Kuipers, Gitta K ^a   Wedekind, Laurine E ^a   Slotman, Ben J ^a   van Rijn, Johannes ^a   Lafleur, Vincent M ^a   Sminia, Peter ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

COX 2 inhibitor; Growth inhibition; Human Glioma cells; Meloxicam; Radiosensitization

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; MELOXICAM;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG SELECTIVITY; ENZYME SPECIFICITY; FLUORESCENCE ACTIVATED CELL SORTING; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IRRADIATION; RADIATION RESPONSE; RADIOSENSITIZATION;

BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; GAMMA RAYS; GLIOMA; HUMANS; RADIATION-SENSITIZING AGENTS; THIAZINES; THIAZOLES; TUMOR STEM CELL ASSAY;

EID: 34548805634     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-007-9385-4     Document Type: Article

References (43)

1. Brada M (1999) Current approaches to radiation therapy for malignant gliomas. Front Radiat Ther Oncol 33:139-149
2. Hulshof MC, Koot RW, Schimmel EC, Dekker F, Bosch DA, Gonzalez GD (2001) Prognostic factors in glioblastoma multiforme. 10 years experience of a single institution. Strahlenther Onkol 177:283-290
3. Slotman BJ, Kralendonk JH, van Alphen HA, Kamphorst W, Karim AB (1996) Hypofractionated radiation therapy in patients with glioblastoma multiforme: Results of treatment and impact of prognostic factors. Int J Radiat Oncol Biol Phys 34:895-898
4. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996
5. Choy H, Milas L (2003) Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: A rational advance? J Natl Cancer Inst 95:1440-1452
6. Shono T, Tofilon PJ, Bruner JM, Owolabi O, Lang FF (2001) Cyclooxygenase-2 expression in human gliomas: Prognostic significance and molecular correlations. Cancer Res 61:4375-4381
7. Khuri FR, Wu H, Lee JJ, Kemp BL, Lotan R, Lippman SM, Feng L, Hong WK, Xu XC (2001) Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 7:861-867
8. New P (2004) Cyclooxygenase in the treatment of glioma: Its complex role in signal transduction. Cancer Control 11:152-164
9. Sminia P, Stoter TR, van der Valk P, Elkhuizen PH, Tadema TM, Kuipers GK, Vandertop WP, Lafleur MV, Slotman BJ (2005) Expression of cyclooxygenase-2 and epidermal growth factor receptor in primary and recurrent glioblastoma multiforme. J Cancer Res Clin Oncol 131:653-661
10. Kern MA, Schoneweiss MM, Sahi D, Bahlo M, Haugg AM, Kasper HU, Dienes HP, Kaferstein H, Breuhahn K, Schirmacher P (2004) Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice. Carcinogenesis 25:1193-1199
11. Nam DH, Park K, Park C, Im YH, Kim MH, Lee S, Hong SC, Shin HJ, Kim JH, Eoh W, McDonnell TJ (2004) Intracranial inhibition of glioma cell growth by cyclooxygenase-2 inhibitor celecoxib. Oncol Rep 11:263-268
12. Tsuchida A, Itoi T, Kasuya K, Endo M, Katsumata K, Aoki T, Suzuki M, Aoki T (2005) Inhibitory effect of meloxicam, a cyclooxygenase-2 inhibitor, on N-nitrosobis (2-oxopropyl) amine induced biliary carcinogenesis in Syrian hamsters. Carcinogenesis 26:1922-1928
13. Dempke W, Rie C, Grothey A, Schmoll HJ (2001) Cyclooxygenase-2: A novel target for cancer chemotherapy? J Cancer Res Clin Oncol 127:411-417
14. Sanchez-Alcazar JA, Bradbury DA, Pang L, Knox AJ (2003) Cyclooxygenase (COX) inhibitors induce apoptosis in non-small cell lung cancer through cyclooxygenase independent pathways. Lung Cancer 40:33-44
15. Amirghahari N, Harrison L, Smith M, Rong X, Naumann I, Ampil F, Shi R, Glass J, Nathan CA (2003) NS 398 radiosensitizes an HNSCC cell line by possibly inhibiting radiation-induced expression of COX-2. Int J Radiat Oncol Biol Phys 57:1405-1412
16. Liu W, Chen Y, Wang W, Keng P, Finkelstein J, Hu D, Liang L, Guo M, Fenton B, Okunieff P, Ding I (2003) Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth. Am J Clin Oncol 26:S103-S109
17. Petersen C, Petersen S, Milas L, Lang FF, Tofilon PJ (2000) Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor. Clin Cancer Res 6:2513-2520
18. Pyo H, Choy H, Amorino GP, Kim JS, Cao Q, Hercules SK, DuBois RN (2001) A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res 7:2998-3005
19. Raju U, Nakata E, Yang P, Newman RA, Ang KK, Milas L (2002) In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: Mechanistic considerations. Int J Radiat Oncol Biol Phys 54:886-894
20. Sminia P, Kuipers G, Geldof A, Lafleur V, Slotman B (2005) COX-2 inhibitors act as radiosensitizer in tumor treatment. Biomed Pharmacother. 2(59 Suppl):S272-S275
21. Milas L (2001) Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse. Semin Radiat Oncol 11:290-299
22. Goldman AP, Williams CS, Sheng H, Lamps LW, Williams VP, Pairet M, Morrow JD, DuBois RN (1998) Meloxicam inhibits the growth of colorectal cancer cells. Carcinogenesis 19:2195-2199
23. Tsubouchi Y, Mukai S, Kawahito Y, Yamada R, Kohno M, Inoue K, Sano H (2000) Meloxicam inhibits the growth of non-small cell lung cancer. Anticancer Res 20:2867-2872
24. Wolfesberger B, Walter I, Hoelzl C, Thalhammer JG, Egerbacher M (2006) Antineoplastic effect of the cyclooxygenase inhibitor meloxicam on canine osteosarcoma cells. Res Vet Sci 80:308-316
25. Wolfesberger B, Hoelzl C, Walter I, Reider GA, Fertl G, Thalhammer JG, Skalicky M, Egerbacher M (2006) In vitro effects of meloxicam with or without doxorubicin on canine osteosarcoma cells. J Vet Pharmacol Ther 29:15-23
26. Ponten J, Westermark B (1978) Properties of human malignant glioma cells in vitro. Med Biol 56:184-193
27. Balmforth AJ, Ball SG, Freshney RI, Graham DI, McNamee HB, Vaughan PF (1986) D-1 dopaminergic and beta-adrenergic stimulation of adenylate cyclase in a clone derived from the human astrocytoma cell line G-CCM. J Neurochem 47:715-719
28. van Bree C, Rodermond HM, de VJ, Haveman J, Franken NA (2005) Mismatch repair proficiency is not required for radioenhancement by gemcitabine 105. Int J Radiat Oncol Biol Phys 62:1504-1509
29. Dohmen K, Okabe H, Ishibashi H (2006) Regression of hepatocellular carcinoma due to cyclooxygenase (COX)-2 inhibitor. Am J Gastroenterol 101:2437-2438
30. Kern MA, Haugg AM, Eiteneuer E, Konze E, Drebber U, Dienes HP, Breuhahn K, Schirmacher P, Kasper HU (2006) Ex vivo analysis of antineoplastic agents in precision-cut tissue slices of human origin: Effects of cyclooxygenase-2 inhibition in hepatocellular carcinoma. Liver Int 26:604-612
31. Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S, Kawai S (2002) Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett 531:278-284
32. Patel MI, Subbaramaiah K, Du B, Chang M, Yang P, Newman RA, Cordon-Cardo C, Thaler HT, Dannenberg AJ (2005) Celecoxib inhibits prostate cancer growth: Evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res 11:1999-2007
33. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS (2000) The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275:11397-11403
34. Grosch S, Maier TJ, Schiffmann S, Geisslinger G (2006) Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 98:736-747
35. Sinclair WK, Morton RA (1966) X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat Res 29:450-474
36. Furuta Y, Hunter N, Barkley T Jr, Hall E, Milas L (1988) Increase in radioresponse of murine tumors by treatment with indomethacin. Cancer Res 48:3008-3013
37. Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, Schror K (1999) Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 59:198-204
38. Hanson WR, DeLaurentiis K (1987) Comparison of in vivo murine intestinal radiation protection by E-prostaglandins. Prostaglandins 33(Suppl):93-104
39. Zaffaroni N, Villa R, Orlandi L, De PA, Del MS, Silvestrini R (1993) Differential effect of 9 beta-chloro-16, 16-dimethyl prostaglandin E2 (nocloprost) on the radiation response of human normal fibroblasts and colon adenocarcinoma cells. Radiat Res 135:88-92
40. Kang K, Wang T, Woon C, Cheah E, Path F, Moore X, Zhu C, Wong M (2007) Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: Inhibition of tumor angiogenesis with extensive tumor necrosis. Int J Radiat Oncol Biol Phys 67:888-896
41. Tegeder I, Pfeilschifter J, Geisslinger G (2001) Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 15:2057-2072
42. Roy S, Banerjee R, Sarkar M (2006) Direct binding of Cu(II)-complexes of oxicam NSAIDs with DNA backbone. J Inorg Biochem 100:1320-1331
43. Kang SG, Kim JS, Park K, Kim JS, Groves MD, Nam DH (2006) Combination celecoxib and temozolomide in C6 rat glioma orthotopic model. Oncol Rep 15:7-13